跳至主要内容
临床试验/NCT07631338
NCT07631338招募中不适用

Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies

Hospital Italiano de Buenos Aires6 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年4月1日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
6

研究概览

简要总结

Low-grade gliomas (LGG) are slow-growing primary brain tumors (WHO grades I-II), and their incidence, survival, and treatment patterns in middle-income settings such as Argentina remain poorly characterized. This retrospective, multicenter study comprises two complementary cohorts:

  1. Cohort 1: The "captive" population covered under the Hospital Italiano de Buenos Aires Health Plan (January 2011-December 2023) to estimate LGG incidence density.
  2. Cohort 2: Histologically confirmed LGG patients treated at the major referral centers to describe overall survival (OS) and disease-free survival (DFS) at 1 and 5 years.

Demographic, clinical, pathological, and treatment data will be collected in a centralized REDCap database.

The primary objective is to describe LGG incidence in Argentina and estimate survival using Kaplan-Meier curves. The secondary objectives include characterizing therapeutic strategies, molecular mutations, and prognostic factors through Cox regression analysis. This registry will fill a critical gap in LGG epidemiology in middle-income countries and generate hypotheses for future research.

详细描述

Background Low-grade gliomas (LGG) represent approximately 6% of primary central nervous system tumors in adults and exhibit unpredictable biological behavior. Although high-income countries have published LGG incidence and survival data stratified by age, sex, and molecular profile, data from Argentina and other middle-income regions are scarce. IDH mutations and other molecular markers, along with clinical factors (age, seizures, tumor volume, and location) and treatment modalities, influence disease progression and prognosis in these patients.

Objectives

  • Primary (Cohort 1): Estimate LGG incidence density in the Hospital Italiano Health Plan population (2011-2023), expressed as cases per 100,000 person-years.
  • Primary (Cohort 2): Describe OS and DFS at 1 and 5 years post-diagnosis.
  • Secondary: Characterize therapeutic strategies (surgical, chemoradiotherapy, monotherapy), molecular profile (IDH, P53, 1p/19q mutations), and identify prognostic factors associated with OS and DFS using multivariable Cox regression.

Design and Scope

This is a retrospective, multicenter, observational cohort study with two cohorts:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Study population cohort 1
  • Inclusion Criteria
  • Adult patients (≥18 years old) affiliated to the health plan of Hospital Italiano de Buenos Aires.
  • Documented clinical follow-up of at least 1 year during the study period.

排除标准

  • Patients not affiliated to the health plan of the Hospital Italiano de Buenos Aires.
  • Study population cohort 2
  • Inclusion Criteria
  • Adult patients (≥18 years) with histopathologically confirmed diagnosis of low-grade glioma (WHO grades I and II).
  • Exclusion Criteria
  • Incomplete or doubtful diagnosis based on histopathologic and molecular criteria.

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ivan A. Huespe

Principal Investigator

Hospital Italiano de Buenos Aires

研究点 (6)

Loading locations...

相似试验